GlassScriptPhysician profile
Ana Turner
NPI 1881318251
$7,893.83
in general payments reported to CMS, 2019-2025
22 companies · $3,926 in 2025
The $3,926 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $481 · 2024: $3,487 · 2025: $3,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,721 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,720.83 |
| Education | $173.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,409.51 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $1,171.80 | 2023-2025 | |
| Lilly USA, LLC | $793.02 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $599.13 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $482.71 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $465.99 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Ardelyx, INC. | $434.96 | 2024-2025 | Ibsrela |
| Pfizer INC. | $336.62 | 2024-2025 | |
| Qol Medical, LLC | $323.15 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $318.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $244.79 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $243.85 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $240.09 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $221.70 | 2024-2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $207.21 | 2025 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $125.00 | 2025 | |
| Redhill Biopharma INC. | $99.80 | 2023-2024 | Talicia |
| Si-Bone, INC. | $84.95 | 2023 | |
| Ironwood Pharmaceuticals, INC | $34.40 | 2023-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $20.14 | 2024 | Bylvay |
| Evoke Pharma, INC. | $19.33 | 2025 | |
| Vivus LLC | $16.73 | 2025 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.